BerGenBio ASA - Registration of reverse share split

03 Jun 2024 18:02 CEST

Bergen, Norway, 3 June 2024. Reference is made to the stock exchange
announcement made by BerGenBio ASA (the "Company") on 23 May 2024 regarding the
Company's annual general meeting resolving a reverse share split of the
Company's shares in the ratio 100:1. The reverse share split has today been
registered with the Norwegian Register of Business Enterprises. Following such
registration, the share capital of the Company is NOK 390,871,160 divided into
39,087,116 shares, each with a nominal value of NOK 10.

For further information, please contact:

Martin Olin, CEO, BerGenBio ASA
ir@bergenbio.com

Rune Skeie, CFO, BerGenBio ASA
rune.skeie@bergenbio.com

About BerGenBio ASA

BerGenBio is a clinical-stage biopharmaceutical company focused on developing
transformative drugs targeting AXL as a potential cornerstone of therapy for
aggressive diseases, including cancer and severe respiratory infections. The
Company is focused on its proprietary lead candidate bemcentinib a potentially
first-in-class selective AXL inhibitor in development for STK11 mutated NSCLC
and severe respiratory infections. BerGenBio is based in Bergen, Norway with a
subsidiary in Oxford, UK. The Company is listed on the Oslo Stock Exchange
(ticker: BGBIO). For more information, visit www.bergenbio.com.

This information is published in accordance with the requirements of the
Continuing Obligations pursuant to Oslo Rule Book II.

More information:
Access the news on Oslo Bors NewsWeb site